LANTUS SOLOSTA U100 by Sanofi (Insulin Glargine) — Reliable Basal Control

Achieve stable glucose management with LANTUS SOLOSTA U100. This premium insulin glargine formulation, manufactured by Sanofi, is designed for steady, long-acting basal control. When you require professional-grade diabetes management, trust in a pharmaceutical-standard solution that prioritizes consistency and patient safety.

Specifications

Product Details & Use Case

LANTUS SOLOSTA U100 is a long-acting insulin analogue specifically designed for daily diabetes management. The science behind this formulation involves the formation of microprecipitates in the subcutaneous tissue, which facilitates a slow, steady release of insulin over a 24-hour period. This mechanism provides consistent basal glucose control, reducing the risk of fluctuations.

Each unit is delivered via a convenient, disposable Solosta pen, ensuring precise dosing and ease of use. Our stock is pharmaceutical-grade, lab-verified, and accompanied by an independent Certificate of Analysis (COA) for every batch, ensuring maximum authenticity and safety.

Shipping & Delivery

We provide discreet and secure shipping to the following locations:

• United States
• United Kingdom
• Canada
• Australia
• Singapore
• Taiwan
• South Korea
• Japan

Estimated Delivery Times:

• United States & Australia: 8–14 working days
• All other countries: 5–7 working days

FAQ

Is LANTUS SOLOSTA the same as other insulin glargine brands?
Yes. The active ingredient is identical, and Sanofi is a globally recognized and reputable pharmaceutical manufacturer.

How should I take LANTUS SOLOSTA U100?
Administration should be via subcutaneous injection using the Solosta pen, typically once daily. Always follow the specific directions provided by your healthcare professional.

How is LANTUS SOLOSTA shipped?
Due to its nature as a liquid solution in a disposable pen, we ship all orders with temperature control and discreet packaging to ensure product integrity upon arrival.